Shots: Novartis to get minority equity in Anthos and will grant rights to Anthos for MAA868 to develop in CVD. Blackstone Life Sciences to fund the joint venture with $250M […]readmore
Tags : Collaborates
Shots: The companies enter into a clinical research collaboration for the evaluation of efficacy and safety of immunotherapy combining Roche’s Tecentriq (atezolizumab) with Immatics’ IMA101 in solid tumors In H2’19, […]readmore
Biosimilars
Biotech
Pharma
Innovent Biosciences Collaborates with Chipscreen to Evaluate Chidamide in Combination
Shots: The companies collaborated to jointly assess safety and efficacy of Chipscreen’s Chidamide in combination with Innovent’s Sintilimab + IBI305 in patients with advanced colorectal carcinoma (ACC) The focus of […]readmore
Shots: Alexion and Caelum collaborate for the development of CAEL-101 in PIa/Ib trial and Caelum to receive $60M as an equity investment, near-term milestones & will conduct P-II trial for […]readmore
Shots: Basilea to conduct the P-I/II biomarker-driven clinical trial with its expected initiation in H1’2019 and Roche to provide atezolizumab for the trial The focus of the agreement is for the onset […]readmore
Shots: BI & BioMed X enters into an agreement to develop strategies for early detection of psychiatric disorders The focus of the agreement is for exploring adolescence’s neurobiology for the […]readmore
Shots: BI to get rights to develop and commercialize bacteriophage lysins using Bioharmony ‘s technology for multi-drug resistant (MDR) Acinetobacter infections caused by Acinetobacter baumannii The focus of the collaboration is […]readmore
Shots: Aduro to receive $12M upfront, up to $620M milestones and royalties on sales from Lilly. Lilly to get rights for Aduro’s cGAS-STING pathway inhibitor program and will be responsible for all costs […]readmore
Shots: AC Immune to receive $80M upfront, $1760M milestones and royalties on sales and Lilly to get WW commercialization rights for AC Immune’s tau aggregation inhibitors and will invest $50M as convertible notes […]readmore
Shots: Instituto Butantan to receive $26M upfront, $75M milestones and royalties on sales from Merck. Merck to get clinical data and learnings (utilized for its TV003, dengue vaccine) from Instituto’s development programs to […]readmore